中國China Patent OfficeCNIPAFeePCT
2024年9月6日

New Fee Standards Released for Chinese Patent Applications

by
劉勇博士
王怡瑾女士

Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE).

Please find our summary below:

PCT application fee deduction rules

 

Application fee & extra fees (claims/pages)

Substantive examination fee

PCT application type

Before

Jul 26, 20242

After

Jul 26, 2024

Before

Jul 26, 2024

After

Jul 26, 2024

CNIPAas RO

CNIPA as ISA or IPEA

100% OFF

100% OFF

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

100% OFF

No discount

20% OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

non-CN as RO

CNIPA as ISA or IPEA

No discount

No discount

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

No discount

No discount

20%OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

  • Abbreviations

    • CNIPA - China National Intellectual Property Administration

    • Non-CN – other patent offices than CNIPA

    • NPE - National Phase Entry

    • IPEA - International Preliminary Examining Authority
  • RO - Receiving Office

  • ISA - International Search Authority

  • EPO - European Patent Office

  • JPO - Japan Patent Office

  • SPO - Swedish Patent Office

Fee standards for PTA/PTE

Under the new fee schedule, the official fee for PTA/PTE requests is CNY 200/patent. If any PTA/PTE request has been filed before July 26, 2024, the PTA/PTE request fee thereof must be paid before October 26, 2024.

If PTA/PTE is granted, the annuity fee during the patent compensation period is CNY 8000/patent/year.

A SPECIAL NOTE: The annuity fee for the patent compensation period must be paid in a lump sum before the expiration of the 20-year patent term. No late payment, restoration, or fee reduction is applicable.

Others

During the implementation period of the patent open license, the annuity fee will be reduced by 15%. If other patent fee reduction policies are also applicable, the most favorable policy can be selected, but only one fee reduction policy may be used per patent.

EIP Thoughts

The new PCT application fee deduction rules are intended to promote CNIPA as the ISA and IPEA for international patent applications.

It has been over four years since PTA/PTE were first introduced in the latest 4th Amendment to the Patent Law. Now we finally have a complete set of procedural requirements for PTA/PTE requests. So far, the procedure has been smooth, and we have already had several requests successfully granted.

We will continue to monitor developments closely and keep you informed of any further updates.

Related Articles

A More Detailed Overview of China’s Patent Term Extension (PTE) System

Everything you need to know about Patent Term Adjustment (PTA) in China

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

    1. Notice on Adjusting and Optimizing Patent Fee Policy, Finance and Taxation [2024] No. 23” and “Notice on the Annual Fee Standard for the Patent Compensation Period and Other Related Matters, Development and Reform Price [2024] No. 1156,” and “Announcement on Adjusting Certain Patent Fee Standards and Reduction Policies (No. 594)” and “Notice on the Payment of Patent Term Compensation Fees and Other Related Matters”.

      ↩︎
    2. Appendix 2 of “Notice of the National Development and Reform Commission and the Ministry of Finance on Reissuing the Administrative and Institutional Fee Standards of the National Intellectual Property Administration and Other Related Issues, Development and Reform Price [2017] No. 270.”

      ↩︎

    其他文章

    Can Post Filing Data Overcome Inventive Step in China?

    2018年11月19日
    Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

    CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law

    2021年10月22日
    Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]

    First ever Invalidation decision on an RNAi Invention patent in China

    2023年12月4日
    Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

    China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

    2022年9月21日
    China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

    我們過去活動

    Top crossarrow-right